Penile Microvascular Arterial Bypass Surgery: Indications, Outcomes, and Complications
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
~Slgnature of Officer
efile GRAPHIC rint - DO NOT PROCESS As Filed Data - DLN:93493312026058 Return of Organization Exempt From Income Tax OMB No 1545-0047 Form990 Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private ~ foundations) 2017 ~ Do not enter social security numbers on this form as It may be made public DepJrtmc-nt of the TreJ~uT"\ Open to Public ~ Information about Form 990 and ItS instructions IS at www IRS qovlform990 Intem~d Re\ C"nuC" ~ef\ Ice Inspection A For th e 2017 ca en d ar year, or t ax year b egmnmg 01 --01 2017 , an d en d'mg 12-- 31 2017 C Name of organization B Check If applicable D Employer Identification number KAISER FOUNDATION HEALTH PLAN INC D Address change 94-1340523 D Name change % CHIEF ACCOUNTING OFFICER D Initial return DOing business as D Final return/terminated E Telephone number D Amended return Number and street (or PObox If mall IS not delivered to street address) IRoom/suite ONE KAISER PLAZA SUITE 15L D Application pending (510) 271-6611 City or town, state or proVince, country, and ZIP or foreign postal code OAKLAND, CA 94612 G Gross receipts $ 68,714,034,750 F Name and address of principal officer H(a) Is this a group return for BERNARD J TYSON ONE KAISER PLAZA SUITE 15L subordinates? OYes ~No OAKLAND, CA 94612 H(b) Are all subordinates Included? OYes ONo I Tax-exempt status ~ 501(c)(3) 0 501(c) ( ) ~ (Insert no ) o 4947(a)(1) or o 527 If "No," attach a list (see instructions) H(c) J Website: ~ www kp org Group exemption number ~ L Year of formation CA K Form of organization ~ Corporation o Trust 0 Association 0 Other ~ 1955 I M State of legal domicile _:£.I [_. -
Treatment of Paraphilias
The World Journal of Biological Psychiatry ISSN: 1562-2975 (Print) 1814-1412 (Online) Journal homepage: https://www.tandfonline.com/loi/iwbp20 The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders Florence Thibaut, Paul Cosyns, John Paul Fedoroff, Peer Briken, Kris Goethals, John M. W. Bradford & The WFSBP Task Force on Paraphilias To cite this article: Florence Thibaut, Paul Cosyns, John Paul Fedoroff, Peer Briken, Kris Goethals, John M. W. Bradford & The WFSBP Task Force on Paraphilias (2020): The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders, The World Journal of Biological Psychiatry To link to this article: https://doi.org/10.1080/15622975.2020.1744723 Published online: 26 May 2020. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=iwbp20 THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY https://doi.org/10.1080/15622975.2020.1744723 REVIEW ARTICLE The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders Florence Thibauta , Paul Cosynsb, John Paul Fedoroffc , Peer Brikend, Kris Goethalse, and f à John M. W. Bradford ; The WFSBP Task Force on Paraphilias aDepartment of Psychiatry and Addictive Disorders, University Hospital Cochin, -
Treatment of Patients with Major Depressive Disorder
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder Third Edition WORK GROUP ON MAJOR DEPRESSIVE DISORDER Alan J. Gelenberg, M.D., Chair Marlene P. Freeman, M.D. John C. Markowitz, M.D. Jerrold F. Rosenbaum, M.D. Michael E. Thase, M.D. Madhukar H. Trivedi, M.D. Richard S. Van Rhoads, M.D., Consultant INDEPENDENT REVIEW PANEL Victor I. Reus, M.D., Chair J. Raymond DePaulo, Jr., M.D. Jan A. Fawcett, M.D. Christopher D. Schneck, M.D. David A. Silbersweig, M.D. This practice guideline was approved in May 2010 and published in October 2010. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST The Work Group on Major Depressive Disorder reports reports receiving honoraria from lectureships for Boeh- the following potentially competing interests for the pe- ringer Ingleheim, Bristol-Myers Squibb, Cyberonics, riod from May 2005 to May 2010: Forest Pharmaceuticals, Inc., Eli Lilly and Company, and Dr. Gelenberg reports consulting for Eli Lilly and Com- Schwartz Pharma. He was involved in the creation of pany, Pfizer, Best Practice, AstraZeneca, Wyeth, Cyber- the Massachusetts General Hospital Psychiatry Academy onics, Novartis, Forest Pharmaceuticals, Inc., GlaxoSmith- (MGH-PA) and has served as a panelist in four satellite Kline, ZARS Pharma, Jazz Pharmaceuticals, Lundbeck, broadcast programs. -
Organisation Mondiale De La Santé Original: English Twenty -First World Health Assembly
INDEXED WORLD HEALTH ORGANIZATION А21 /P &B /16 9 May 1968 ORGANISATION MONDIALE DE LA SANTÉ ORIGINAL: ENGLISH TWENTY -FIRST WORLD HEALTH ASSEMBLY Agenda item 2.11.2 PHARMACEUTICAL ADVERTISING Report by the Director -General 1. In resolution WНА2О.35, the Twentieth World Health Assembly requested the Director -General to study the ethical and scientific criteria that, from the medical point of view, should govern the advertising of drugs, and to report thereon to the Executive Board and to the Twenty - first World Health Assembly. 2. At its forty -first session the Executive Board had before it a progress report by the Director -General together with a survey of the legislation on pharmaceutical advertising in twenty -two countries which had been published by WHO in 1961.1 The Executive Board was informed that the Secretariat had commenced the revision of this survey which had been rendered necessary by new legislation enacted in many countries since 1961. The revised survey, as it will be published in Volume 19 (1968) of the International Digest of Health Legislation, is attached. 3. The new survey covers the legislation on pharmaceutical advertising in twenty -six countries. It has made it possible to identify more precisely the principles applied by Member States to the regulation of pharmaceutical advertising and to suggest the formulation of criteria with a view to ensuring their widest possible acceptance. 4. As the analysis of existing legislation shows, medical advertising (also called "technical" advertising) was virtually unrestricted in a number of countries until quite recently, whereas advertising addressed to the public is generally subject to more or less strict legislative provisions.